Magnetic source imaging developer Biomagnetic Technologies ofSan Diego last month announced the sale of a Magnes 2500 WH systemto the University of Konstanz in Germany. The university willuse the scanner to conduct psychiatric research.The order is the
Magnetic source imaging developer Biomagnetic Technologies ofSan Diego last month announced the sale of a Magnes 2500 WH systemto the University of Konstanz in Germany. The university willuse the scanner to conduct psychiatric research.
The order is the eighth for BTI's new Whole Head scanner, whichsells for between $1.5 million and $2.5 million (SCAN 3/15/95).BTI began shipping Magnes 2500 WH systems to international customersin July.
BTI cited the delay in Magnes 2500 WH shipments as the reasonfor a sharp drop in revenue for its first nine months (end-June).BTI posted revenues of $865,000 and a net loss of $9.2 million,compared with revenues of $6.1 million and a net loss of $5.7million in the same period a year ago.
In other news, BTI received 510(k) clearance for its Magnes IIMSI device. BTI hopes that the agency's familiarity with MagnesII will pay off in its review of Magnes Whole Head, a more sophisticatedMSI scanner that entered the 510(k) process in July. The WholeHead scanner employs 148 channels, twice as many as Magnes II,and BTI plans to emphasize Whole Head sales when that productis cleared.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.